Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Sparkes A, De Baetselier P, Brys L, Cabrito I, Sterckx YG, Schoonooghe S, Muyldermans S, Raes G, Bucala R, Vanlandschoot P, Van Ginderachter JA, Stijlemans B.

FASEB J. 2018 Jun;32(6):3411-3422. doi: 10.1096/fj.201701189R. Epub 2018 Jan 25.

2.

MIF-Mediated Hemodilution Promotes Pathogenic Anemia in Experimental African Trypanosomosis.

Stijlemans B, Brys L, Korf H, Bieniasz-Krzywiec P, Sparkes A, Vansintjan L, Leng L, Vanbekbergen N, Mazzone M, Caljon G, Van Den Abbeele J, Odongo S, De Trez C, Magez S, Van Ginderachter JA, Beschin A, Bucala R, De Baetselier P.

PLoS Pathog. 2016 Sep 15;12(9):e1005862. doi: 10.1371/journal.ppat.1005862. eCollection 2016 Sep.

3.

M-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment.

Van Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, Brys L, Abels C, Lahmar Q, Ergen C, Vereecke L, Tacke F, De Baetselier P, Van Ginderachter JA, Laoui D.

Cancer Res. 2016 Jan 1;76(1):35-42. doi: 10.1158/0008-5472.CAN-15-0869. Epub 2015 Nov 16.

4.

MIF contributes to Trypanosoma brucei associated immunopathogenicity development.

Stijlemans B, Leng L, Brys L, Sparkes A, Vansintjan L, Caljon G, Raes G, Van Den Abbeele J, Van Ginderachter JA, Beschin A, Bucala R, De Baetselier P.

PLoS Pathog. 2014 Sep 25;10(9):e1004414. doi: 10.1371/journal.ppat.1004414. eCollection 2014 Sep.

5.

The molecular mechanism of Shiga toxin Stx2e neutralization by a single-domain antibody targeting the cell receptor-binding domain.

Lo AW, Moonens K, De Kerpel M, Brys L, Pardon E, Remaut H, De Greve H.

J Biol Chem. 2014 Sep 5;289(36):25374-81. doi: 10.1074/jbc.M114.566257. Epub 2014 Jul 22.

6.

Origin and functional diversification of an amphibian defense peptide arsenal.

Roelants K, Fry BG, Ye L, Stijlemans B, Brys L, Kok P, Clynen E, Schoofs L, Cornelis P, Bossuyt F.

PLoS Genet. 2013;9(8):e1003662. doi: 10.1371/journal.pgen.1003662. Epub 2013 Aug 1.

7.

Pivotal Advance: Arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes.

Van den Bossche J, Lamers WH, Koehler ES, Geuns JM, Alhonen L, Uimari A, Pirnes-Karhu S, Van Overmeire E, Morias Y, Brys L, Vereecke L, De Baetselier P, Van Ginderachter JA.

J Leukoc Biol. 2012 May;91(5):685-99. doi: 10.1189/jlb.0911453. Epub 2012 Mar 13.

PMID:
22416259
8.

High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis.

Stijlemans B, Caljon G, Natesan SK, Saerens D, Conrath K, Pérez-Morga D, Skepper JN, Nikolaou A, Brys L, Pays E, Magez S, Field MC, De Baetselier P, Muyldermans S.

PLoS Pathog. 2011 Jun;7(6):e1002072. doi: 10.1371/journal.ppat.1002072. Epub 2011 Jun 16.

9.

Scrutinizing the mechanisms underlying the induction of anemia of inflammation through GPI-mediated modulation of macrophage activation in a model of African trypanosomiasis.

Stijlemans B, Vankrunkelsven A, Brys L, Raes G, Magez S, De Baetselier P.

Microbes Infect. 2010 May;12(5):389-99. doi: 10.1016/j.micinf.2010.02.006. Epub 2010 Mar 1.

PMID:
20197106
10.

Identification of a parasitic immunomodulatory protein triggering the development of suppressive M1 macrophages during African trypanosomiasis.

Gómez-Rodríguez J, Stijlemans B, De Muylder G, Korf H, Brys L, Berberof M, Darji A, Pays E, De Baetselier P, Beschin A.

J Infect Dis. 2009 Dec 15;200(12):1849-60. doi: 10.1086/648374.

PMID:
19911988
11.

Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB.

Porta C, Rimoldi M, Raes G, Brys L, Ghezzi P, Di Liberto D, Dieli F, Ghisletti S, Natoli G, De Baetselier P, Mantovani A, Sica A.

Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14978-83. doi: 10.1073/pnas.0809784106. Epub 2009 Aug 17.

12.

IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection.

Guilliams M, Movahedi K, Bosschaerts T, VandenDriessche T, Chuah MK, Hérin M, Acosta-Sanchez A, Ma L, Moser M, Van Ginderachter JA, Brys L, De Baetselier P, Beschin A.

J Immunol. 2009 Jan 15;182(2):1107-18.

13.

Role of iron homeostasis in trypanosomiasis-associated anemia.

Stijlemans B, Vankrunkelsven A, Brys L, Magez S, De Baetselier P.

Immunobiology. 2008;213(9-10):823-35. doi: 10.1016/j.imbio.2008.07.023. Epub 2008 Sep 7.

PMID:
18926297
14.

Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P.

Bosschaerts T, Guilliams M, Noel W, Hérin M, Burk RF, Hill KE, Brys L, Raes G, Ghassabeh GH, De Baetselier P, Beschin A.

J Immunol. 2008 May 1;180(9):6168-75.

15.

A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-associated immunopathology.

Stijlemans B, Baral TN, Guilliams M, Brys L, Korf J, Drennan M, Van Den Abbeele J, De Baetselier P, Magez S.

J Immunol. 2007 Sep 15;179(6):4003-14.

16.

The metastatic T-cell hybridoma antigen/P-selectin glycoprotein ligand 1 is required for hematogenous metastasis of lymphomas.

Raes G, Ghassabeh GH, Brys L, Mpofu N, Verschueren H, Vanhecke D, De Baetselier P.

Int J Cancer. 2007 Dec 15;121(12):2646-52.

17.

African trypanosomiasis: naturally occurring regulatory T cells favor trypanotolerance by limiting pathology associated with sustained type 1 inflammation.

Guilliams M, Oldenhove G, Noel W, Hérin M, Brys L, Loi P, Flamand V, Moser M, De Baetselier P, Beschin A.

J Immunol. 2007 Sep 1;179(5):2748-57.

18.

N-terminal truncation enables crystallization of the receptor-binding domain of the FedF bacterial adhesin.

De Kerpel M, Van Molle I, Brys L, Wyns L, De Greve H, Bouckaert J.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Dec 1;62(Pt 12):1278-82. Epub 2006 Nov 30.

19.

Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions.

Ghassabeh GH, De Baetselier P, Brys L, Noël W, Van Ginderachter JA, Meerschaut S, Beschin A, Brombacher F, Raes G.

Blood. 2006 Jul 15;108(2):575-83. Epub 2006 Mar 23.

20.

Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer.

Van Ginderachter JA, Meerschaut S, Liu Y, Brys L, De Groeve K, Hassanzadeh Ghassabeh G, Raes G, De Baetselier P.

Blood. 2006 Jul 15;108(2):525-35. Epub 2006 Mar 9.

21.

Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing.

Saerens D, Frederix F, Reekmans G, Conrath K, Jans K, Brys L, Huang L, Bosmans E, Maes G, Borghs G, Muyldermans S.

Anal Chem. 2005 Dec 1;77(23):7547-55.

PMID:
16316161
22.

Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar procollagens types I-III and V.

Colige A, Ruggiero F, Vandenberghe I, Dubail J, Kesteloot F, Van Beeumen J, Beschin A, Brys L, Lapière CM, Nusgens B.

J Biol Chem. 2005 Oct 14;280(41):34397-408. Epub 2005 Jul 26.

23.

Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection.

Brys L, Beschin A, Raes G, Ghassabeh GH, Noël W, Brandt J, Brombacher F, De Baetselier P.

J Immunol. 2005 May 15;174(10):6095-104.

24.

Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation.

Raes G, Brys L, Dahal BK, Brandt J, Grooten J, Brombacher F, Vanham G, Noël W, Bogaert P, Boonefaes T, Kindt A, Van den Bergh R, Leenen PJ, De Baetselier P, Ghassabeh GH.

J Leukoc Biol. 2005 Mar;77(3):321-7. Epub 2004 Dec 9.

PMID:
15591125
25.

FIZZ1 and Ym as tools to discriminate between differentially activated macrophages.

Raes G, Noël W, Beschin A, Brys L, de Baetselier P, Hassanzadeh GH.

Dev Immunol. 2002 Sep;9(3):151-9.

26.

Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells.

Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB.

J Immunol. 2003 May 15;170(10):5064-74.

27.

Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells.

Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H.

Proc Natl Acad Sci U S A. 2003 May 13;100(10):5778-82. Epub 2003 May 5.

28.

Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells.

Nguyen VK, Zou X, Lauwereys M, Brys L, Brüggemann M, Muyldermans S.

Immunology. 2003 May;109(1):93-101.

29.

Infection stage-dependent modulation of macrophage activation in Trypanosoma congolense-resistant and -susceptible mice.

Noël W, Hassanzadeh G, Raes G, Namangala B, Daems I, Brys L, Brombacher F, Baetselier PD, Beschin A.

Infect Immun. 2002 Nov;70(11):6180-7.

30.

Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.

Cote-Sierra J, Bredan A, Toldos CM, Stijlemans B, Brys L, Cornelis P, Segovia M, de Baetselier P, Revets H.

Infect Immun. 2002 Jan;70(1):240-8.

31.

Relative contribution of interferon-gamma and interleukin-10 to resistance to murine African trypanosomosis.

Namangala B, Noël W, De Baetselier P, Brys L, Beschin A.

J Infect Dis. 2001 Jun 15;183(12):1794-800. Epub 2001 May 15.

PMID:
11372033
32.

Alternative versus classical macrophage activation during experimental African trypanosomosis.

Baetselier PD, Namangala B, Noël W, Brys L, Pays E, Beschin A.

Int J Parasitol. 2001 May 1;31(5-6):575-87. Review.

PMID:
11334945
33.

Alternative versus classical macrophage activation during experimental African trypanosomosis.

Namangala B, De Baetselier P, Noël W, Brys L, Beschin A.

J Leukoc Biol. 2001 Mar;69(3):387-96.

PMID:
11261785
34.

Trypanosoma brucei brucei infection impairs MHC class II antigen presentation capacity of macrophages.

Namangala B, Brys L, Magez S, De Baetselier P, Beschin A.

Parasite Immunol. 2000 Jul;22(7):361-70.

35.

Hemozoin is a key factor in the induction of malaria-associated immunosuppression.

Scorza T, Magez S, Brys L, De Baetselier P.

Parasite Immunol. 1999 Nov;21(11):545-54.

36.

Convergent evolution of cytokines.

Beschin A, Bilej M, Brys L, Torreele E, Lucas R, Magez S, De Baetselier P.

Nature. 1999 Aug 12;400(6745):627-8. No abstract available.

PMID:
10458158
37.

Identification of a coelomic mitogenic factor in Eisenia foetida earthworm.

Hanusová R, Bilej M, Brys L, De-Baetselier P, Beschin A.

Immunol Lett. 1999 Feb;65(3):203-11.

PMID:
10065744
38.

Isolation and characterization of single-chain Fv genes encoding antibodies specific for Drosophila Poxn protein.

Hassanzadeh GH G, De Silva KS, Dambly-Chaudière C, Brys L, Ghysen A, Hamers R, Muyldermans S, De Baetselier P.

FEBS Lett. 1998 Oct 16;437(1-2):75-80. Erratum in: FEBS Lett 1999 Jan 22;443(1):80.

39.

Identification and cloning of a glucan- and lipopolysaccharide-binding protein from Eisenia foetida earthworm involved in the activation of prophenoloxidase cascade.

Beschin A, Bilej M, Hanssens F, Raymakers J, Van Dyck E, Revets H, Brys L, Gomez J, De Baetselier P, Timmermans M.

J Biol Chem. 1998 Sep 18;273(38):24948-54.

40.

Trypanosoma brucei infection elicits nitric oxide-dependent and nitric oxide-independent suppressive mechanisms.

Beschin A, Brys L, Magez S, Radwanska M, De Baetselier P.

J Leukoc Biol. 1998 Apr;63(4):429-39.

PMID:
9544572
41.

Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model.

Raes G, Van Ginderachter J, Liu YQ, Brys L, Thielemans K, De Baetselier P, Geldhof A.

Cancer Immunol Immunother. 1998 Jan;45(5):257-65.

PMID:
9439649
42.
43.

Development of new cloning vectors for the production of immunogenic outer membrane fusion proteins in Escherichia coli.

Cornelis P, Sierra JC, Lim A Jr, Malur A, Tungpradabkul S, Tazka H, Leitão A, Martins CV, di Perna C, Brys L, De Baetseller P, Hamers R.

Biotechnology (N Y). 1996 Feb;14(2):203-8.

PMID:
9636324
44.

Identification of a cytolytic protein in the coelomic fluid of Eisenia foetida earthworms.

Bilej M, Brys L, Beschin A, Lucas R, Vercauteren E, Hanusová R, De Baetselier P.

Immunol Lett. 1995 Feb;45(1-2):123-8.

PMID:
7622179
45.

Analysis of HIV infections in human macrophage-like cell lines.

Brys L, Van Gyseghem A, Verhaegen S, Saman E, De Baetselier P.

Adv Exp Med Biol. 1994;355:183-7. No abstract available.

PMID:
7709820
46.
47.

Redistribution of a murine humoral immune response following removal of an immunodominant B cell epitope from a recombinant fusion protein.

Scheerlinck JP, DeLeys R, Saman E, Brys L, Geldhof A, De Baetselier P.

Mol Immunol. 1993 Jun;30(8):733-9.

PMID:
7684820
48.

A monoclonal antibody against peripheral benzodiazepine receptor activities the human neutrophil NADPH-oxidase.

Zavala F, Masson A, Brys L, de Baetselier P, Descamps-Latscha B.

Biochem Biophys Res Commun. 1991 May 15;176(3):1577-83.

PMID:
1645547
49.

Differential presentation of hepatitis B S-preS(2) particles and peptides by macrophages and B-cell like antigen-presenting cells.

Scheerlinck JP, Burssens G, Brys L, Michel A, Hauser P, De Baetselier P.

Immunology. 1991 May;73(1):88-94.

50.

TNF-alpha mediated selection of macrophage-resistant gene-regulatory tumor variants.

Remels L, Neirynck A, Brys L, Vercauteren E, De Baetselier P.

Clin Exp Metastasis. 1989 Sep-Oct;7(5):493-506.

PMID:
2473862

Supplemental Content

Support Center